Guidance In The Works For Unmet Need In Serious Bacterial Infections
• By Shirley Haley
CHICAGO – FDA hopes to have a draft guidance for industry on developing antibiotics for serious bacterial infection with unmet medical need ready for public review in the first quarter of 2012, Edward Cox, director of FDA’s Office of Antimicrobial Products, told an audience at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?
Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."